Needham analyst Ami Fadia downgraded Seagen (SGEN) to Hold from Buy after Pfizer (PFE) announced it will acquire Seagen for $229 in cash per Seagen share for a total enterprise value of $43B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SGEN: